AARS1 and esophageal squamous cell carcinoma: Inspiringly, the combination of stiripentol and elesclomol exerts a strong suppressive effect on ESCC, suggesting that targeting NUDT21, AARS1, or LDHA alongside elesclomol may represent a promising therapeutic strategy for ESCC treatment.